Groups
Company Size (Fulltime employees)
Partnering Objectives
Functionality
Headquartner in China
Biotech/Pharma Category
Biotech/Pharma Asset Stage
Medtech Category
Medtech Development Stage
Index
Countries
Reset

Mira Life Science Ventures United States

Mira Life Science Ventures was established to change the paradigm for investment, incubation and development of new disruptive and game-changing technologies in the life sciences. Mira LSV will invest in medical devices, therapeutics, diagnostics, enabling technologies and digital healthcare. Mira LSV will focus its efforts in areas of significant unmet medical needs such as cancer, neurological diseases, infectious disease, autoimmune disease, inflammatory diseases, personalized medicine, cardiovascular disease and renal diseases.

In order to change the venture investment paradigm, Mira LSV was formed to break out of the traditional venture model and move to a more flexible, nimble and shareholder-centric model to accelerate development of these break-through products and technologies and bring them to patients. Mira LSV’s highly flexible business structure, broad and diverse access to deal-flow and highly experienced management team will ensure we have a significant positive impact on our healthcare system.

Website:
Mira Life Science Ventures
Company Size (Fulltime employees)
1-10
Year of foundation
2020
Partnering Objectives
Please specify your partnering goal
Seeking seed investments into Mira Life with global diversity
Headquartner in China
No
Biotech/Pharma Category
Medtech Category
Slides Deck
(pptx, 11.98MB)
Mr. Mel Rothberg
Chairman 
Functionality
Management

MissionBio United States

Single cell multi-omics company to eradicate cancer
Website:
Missionbio.com
Company Size (Fulltime employees)
1-10
Partnering Objectives
Please specify your partnering goal
To expand user base and market
Headquartner in China
No
Ms. Yue Wang
Fas 
Functionality
Sales and Marketing

Mito Biopharma United States

Mitochondria play a central role in metabolic diseases and cancer. Targeting mitochondria for therapeutic development provides a unique opportunity for the effective treatment of these devastating diseases, including nonalcoholic steatohepatitis (NASH), type 2 diabetes (T2D), and various cancers.

Mito Biopharma is a leading company in designing safe chemical mitochondrial uncouplers for
therapeutic development. We have developed a transformative and proven platform technology supporting lead development. Proof-of-concept studies demonstrated broad applications of the platform and superiority of mechanism of action. Therapeutic leads are protected by strong IP protection (worldwide composition-of-matter patent protection). The technology impacts high-value markets including NASH/T2D, Covid-19, and cancer.

We have IND- leads for NASH/T2D, Covid-19, and liver metastatic cancer. Our current focus is on a NASH lead. The company is seeking resources to support the NASH lead for IND and Phase I development, as well as pipeline development.
Website:
www.mitobiopharma.com
Company Size (Fulltime employees)
1-10
Year of foundation
2012
Partnering Objectives
Please specify your partnering goal
Development of a drug lead to clinical stage
Headquartner in China
No
Biotech/Pharma Category
Assets Information 1
MB-W53A|Small molecule NASH IND Lead|NASH|
Assets Information 2
WB-W53B|Small molecule Covid IND lead|Covid-19|
Biotech/Pharma Asset Stage
Dr. "Victor" Shengkan Jin
Founder and CEO 
Functionality
Management

MSA Capital United States

MSA manages over $1.5 billion and invests in global leading early and growth-stage technology-enabled companies.
Website:
http://msacap.com/
Company Size (Fulltime employees)
1-10
Partnering Objectives
Please specify your partnering goal
Invest in startups
Headquartner in China
Yes
Dr. Kou Qin
VP 
Functionality
Investment

MSQ Ventures United States

MSQ Ventures is a New York-based cross-border advisory firm that bridges the healthcare industries globally by offering our deep knowledge, strong network, and local insights into the China market. We provide comprehensive advisory services for our clients’ cross-border projects: market assessment, in/out-licensing, joint ventures, and PR&IR. We currently have offices in New York (headquarter), Beijing, Shanghai, and Shenzhen.
Website:
http://msqventures.com/
Company Size (Fulltime employees)
1-10
Partnering Objectives
Please specify your partnering goal
in and out licensing
Headquartner in China
No
Biotech/Pharma Category
Mr. Estigarribia Marc
MD 

Myriad Genetics United States

Myriad Genetics is a technology-enabled molecular diagnostics company, with worldwide presence. Our genetic tests play in Oncology, Women's Health (e.g., prenatal), and Mental Health areas. 

Website:
https://myriad.com/products-services/all-products/overview/
Company Size (Fulltime employees)
1001-5000
Year of foundation
1991
Partnering Objectives
Please specify your partnering goal
Win-win
Headquartner in China
No
Biotech/Pharma Category
Slides Deck
(pdf, 617.13KB)
Jackie Z
Business Development Lead 
Functionality
Business Development

NanoTech Pharma Inc United States

NanoTech Pharma focus on nanomedicine formulation development, located in New Jersey USA since year 2018. We have rich experiences in liposome and nanocrystal drug delivery systems. Our pipelines include 2 ANDA and several 505(b)(2) drugs, some of which have filed patents and are moving up to commercial scale.
Website:
www.NanoTech-Pharma.com
Company Size (Fulltime employees)
1-10
Year of foundation
2018, 10 FTEs
Partnering Objectives
Please specify your partnering goal
Equity funding and pipeline co-development
Headquartner in China
No
Biotech/Pharma Category
Ms. Ruby Sun
Vice President of Business Development 
Functionality
Business Development

NeoProgen United States

Cardiac Focused Stem Cell /Secretome Exosome company . Immortalized cell line
Website:
Www.NeoProgen.com
Company Size (Fulltime employees)
1-10
Year of foundation
2018
Partnering Objectives
Please specify your partnering goal
Out license Assets
Headquartner in China
No
Assets Information 1
Neo3002|Immortalized cell line|Heart Failure / AKI|None yet
Biotech/Pharma Asset Stage
Mr. Bill Niland
CEO 
Functionality
Management

NGM Biopharmaceuticals United States

We are a clinical stage biopharmaceutical company advancing a robust pipeline of drug candidates to address a spectrum of large, unmet medical needs. We are focused on harnessing powerful, untapped biology underlying major diseases to develop transformative therapeutics for patients.
Website:
www.ngmbio.com
Partnering Objectives
Headquartner in China
No
David Shen
SVP, Biologics Research and CMC 

North American Rep. Office of Shenzhen United States

The North American Representative Office of Shenzhen, P. R. China (NAROS) is a U.S. based, business service provider representing the City of Shenzhen, China´s first Special Economic Zone. Directly sponsored by the Shenzhen Municipal Government and Invest Shenzhen, NAROS offers guidance and consultation to North American companies wishing to enter the Chinese market by means of direct investment within in the City of Shenzhen, as well as to Shenzhen-based companies looking to enter the North American market.
Website:
www.shenzhenoffice.org
Company Size (Fulltime employees)
1-10
Partnering Objectives
Please specify your partnering goal
providing consulting service for entities interested to find opportunities in Shenzhen
Headquartner in China
Yes
Mr. Paul Xu
Business Development Specialist 
Functionality
Business Development